Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

The researchers found that Zeb2 acts as a master switch. When the gene is active, it turns macrophages into cancer supporters ...

In a remarkable medical breakthrough, researchers from Israel, the United States, and China—led by the Weizmann Institute of Science—have developed an innovative genetic method that transforms ...

An international team of researchers from Israel, the United States, and China has developed a genetic method to ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

A surprising link between the immune system and brain behavior is emerging, as new research reveals how a single immune ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously ...

In a study published in Science, a research team led by Prof. Ye Jian from the Institute of Microbiology of the Chinese ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...